Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis

NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of CFTR mutations within the criteria set out in this statement.

SPS commentary:

This commissioning statement supersedes previous relevant clinical commissioning policies. The treatments will be available through the access agreement in place between NHS England and Vertex pharmaceuticals.

NHS England